DMKJ
RLMD icon

David M. Knott Jr’s Relmada Therapeutics RLMD Stock Holding History

David M. Knott Jr’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.12M Buy
451,000
+11,700
+3% +$81.8K 1.65% 18
2026
Q1 		$3.06M Buy
+439,300
New +$2.08M 1.82% 16
2022
Q1 		– Sell
-6,000
Closed -$135K – 147
2021
Q4 		$135K Buy
+6,000
New +$133K 0.05% 96

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

David M. Knott Jr's RLMD Position: Q2 2026 in Review

David M. Knott Jr increased its Relmada Therapeutics (RLMD) stake by 2.7% in Q2 2026, buying an estimated $81.8K and bringing the position to 451,000 shares worth $3.12M. The position accounts for 1.65% of the portfolio, ranked #18.

David M. Knott Jr first reported a position in RLMD in Q4 2021 and has held it in 3 quarters since. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • David M. Knott Jr held 451,000 shares of Relmada Therapeutics worth $3.12M as of Q2 2026.
  • David M. Knott Jr bought 11,700 Relmada Therapeutics shares in Q2 2026, an estimated $81.8K.
  • Relmada Therapeutics made up 1.65% of David M. Knott Jr's portfolio in Q2 2026, its #18 holding.
  • David M. Knott Jr first reported a position in Relmada Therapeutics in Q4 2021 and has held it in 3 quarters since.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on David M. Knott Jr's 13F filing for Q2 2026, filed 12 Aug 2026.